Biogen (BIIB)
(Real Time Quote from BATS)
$201.85 USD
-3.10 (-1.51%)
Updated Sep 5, 2024 01:34 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
BIIB 201.85 -3.10(-1.51%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
Other News for BIIB
Optimistic Buy Rating for Biogen on Strategic Cost-Cutting and Growth Asset Prioritization
IN BRIEF: Biogen shares positive results for higher nusinersen dose
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder
Key Takeaways From Biogen Analyst Ratings
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA